Clinical aspects
Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis
E. Ochoa1, J.-E. Martin2, S. Assasi3, L. Beretta4, P. Carreira5, A. Guillén6, C.P. Simeón7, E. Koumakis8, P. Dieude9, Y. Allanore10, F.J. García-Hernández11, G. Espinosa12, I. Castellví13, J.L. Trapiella14, L. Rodriguez15, M.A. González-Gay16, M.V. Egurbide17, L. Sáez18, J.L. Callejas-Rubio19, J.A. Vargas-Hitos20, N. Hunzelmann21, G. Riemekasten22, T. Witte23, J.H. Distler24, A. Kreuter25, C. Lunardi26, A. Santaniello27, F.K. Tan28, P.G. Shiels29, A.L. Herrick30, J. Worthington31, M.C. Vonk32, B.P. Koeleman33, T.R. Radstake34, M.D. Mayes35, J. Martin36, A. The Spanish Scleroderma Group
- Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain. eguzki8A@gmail.com
- Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain.
- The University of Texas Health Science Center-Houston, Houston, TX, USA.
- Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggioire Policlinico di Milano, Milan, Italy.
- Department of Rheumatology, Hospital 12 de Octubre, Madrid, Spain.
- Department of Internal Medicine, Hospital Valle de Hebrón, Barcelona, Spain.
- Department of Internal Medicine, Hospital Valle de Hebrón, Barcelona, Spain.
- INSERM, Institut Cochin, Cochin Hospital, AP-HP, INSERM U1016, Sorbonne Paris Cité, and Paris Descartes University, Paris, France.
- Paris Diderot University, INSERM U699, and Hôpital Bichat Claude Bernard, AP-HP, Paris, France.
- INSERM, Institut Cochin, Cochin Hospital, AP-HP, INSERM U1016, Sorbonne Paris Cité, and Paris Descartes University, Paris, France.
- Department of Internal Medicine, Hospital Virgen del Rocío, Sevilla, Spain.
- Department of Internal Medicine, Autoimmune Diseases Unit, Hospital Clínico, Barcelona, Spain.
- Department of Rheumatology, Hospital Universitario de la Santa Creu y Sant Pau, Barcelona, Spain.
- Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Spain.
- Department of Rheumatology, Hospital Clínico Universitario San Carlos, Madrid, Spain.
- Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IFIMAV, Santander, Spain.
- Department of Internal Medicine, Hospital Universitario Cruces, Barakaldo, Spain.
- Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitario Miguel Servet, Zaragoza, Spain.
- Department of Systemic Autoimmune Diseases, Hospital Clínico Universitario San Cecilio, Granada, Spain.
- Department of Internal Medicine, Hospital Virgen de las Nieves, Granada, Spain.
- Department of Dermatology, University of Cologne, Cologne, Germany.
- Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany.
- Department of Clinical Immunology, Hannover Medical School, Hannover, Germany.
- Department of Internal Medicine, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
- Department of Dermatology, Venereology, and Allergology, Ruhr-University Bochum, Bochum, Germany.
- Department of Medicine, Università degli Studi di Verona, Verona, Italy.
- Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggioire Policlinico di Milano, Milan, Italy.
- The University of Texas Health Science Center-Houston, Houston, TX, USA.
- Section of Epigenetics, Institute of Cancer Sciences, MVLS, University of Glasgow, Glasgow, UK.
- Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
- Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
- Department of Rheumatology, Radboud University, Nijmegen Medical Centre, Nijmegen HC, The Netherlands.
- Section Complex Genetics, Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
- Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, The Netherlands.
- The University of Texas Health Science Center-Houston, Houston, TX, USA.
- Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain.
CER8166
2015 Vol.33, N°4 ,Suppl.91
PI 0031, PF 0035
Clinical aspects
Free to view
(click on article PDF icon to read the article)
PMID: 26314374 [PubMed]
Received: 01/12/2014
Accepted : 27/03/2015
In Press: 27/08/2015
Published: 31/08/2015
Abstract
OBJECTIVES:
The current knowledge of the influence of systemic sclerosis (SSc) risk loci in the clinical sub-phenotypes is still limited. The main limitation lies in the low frequency of some sub-phenotypes which could be solved by replication studies in independent cohorts and meta-analysis between studies. In this regard, CCR6 gene variants have been recently associated with anti-topoisomerase I positive (ATA+) production in SSc patients in a candidate gene study. This gene has been proposed to have a critical role in IL-17-driven autoimmunity in human diseases.
METHODS:
In order to confirm the association between CCR6 and ATA+ SSc patients, we performed an independent replication study in populations of European ancestry. We studied two CCR6 genetic variants (rs968334 and rs3093024) in a total of 901 ATA+ SSc cases, 3,258 ATA- SSc cases and 7,865 healthy controls and compared allelic frequencies for those SNPs in ATA+ SSc with healthy controls and also with ATA- SSc patients.
RESULTS:
The comparison performed between ATA+ SSc patients and healthy controls showed significant association with SNP rs968334 (p=4.88 x 10-2, OR=1.11). When we compared ATA+ SSc cases with ATA- SSc, both SNPs, rs3093024 and rs968334, showed significant associations (p=2.89 x 10-2, OR=1.13; p=1.69 x 10-2, OR=1.15). Finally, in order to increase even more sample size and statistical power, we meta-analysed our study with the previous reported and found a significant association between SNP rs3093024 and ATA+ SSc patients (p=1.00 x 10-4, OR=1.16) comparing with healthy controls.
CONCLUSIONS:
Our work confirms the association of CCR6 gene and ATA+ SSc patients.